AR054448A1 - Composiciones farmaceuticas que comprenden acido arsenioso, su sal de sodio y sus derivados destinada al tratamiento de cancer urogenital y de su metastasis - Google Patents
Composiciones farmaceuticas que comprenden acido arsenioso, su sal de sodio y sus derivados destinada al tratamiento de cancer urogenital y de su metastasisInfo
- Publication number
- AR054448A1 AR054448A1 ARP060101851A ARP060101851A AR054448A1 AR 054448 A1 AR054448 A1 AR 054448A1 AR P060101851 A ARP060101851 A AR P060101851A AR P060101851 A ARP060101851 A AR P060101851A AR 054448 A1 AR054448 A1 AR 054448A1
- Authority
- AR
- Argentina
- Prior art keywords
- pharmaceutical compositions
- arsenious acid
- treatment
- metastasis
- sodium salt
- Prior art date
Links
- GOLCXWYRSKYTSP-UHFFFAOYSA-N Arsenious Acid Chemical compound O1[As]2O[As]1O2 GOLCXWYRSKYTSP-UHFFFAOYSA-N 0.000 title abstract 4
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 4
- 206010027476 Metastases Diseases 0.000 title 1
- 208000008385 Urogenital Neoplasms Diseases 0.000 title 1
- 230000009401 metastasis Effects 0.000 title 1
- NOJNFULGOQGBKB-UHFFFAOYSA-M sodium;3-[3-tert-butylsulfanyl-1-[[4-(6-ethoxypyridin-3-yl)phenyl]methyl]-5-[(5-methylpyridin-2-yl)methoxy]indol-2-yl]-2,2-dimethylpropanoate Chemical compound [Na+].C1=NC(OCC)=CC=C1C(C=C1)=CC=C1CN1C2=CC=C(OCC=3N=CC(C)=CC=3)C=C2C(SC(C)(C)C)=C1CC(C)(C)C([O-])=O NOJNFULGOQGBKB-UHFFFAOYSA-M 0.000 title 1
- 208000037964 urogenital cancer Diseases 0.000 title 1
- 229910052783 alkali metal Inorganic materials 0.000 abstract 3
- -1 alkaline earth metal salt Chemical class 0.000 abstract 3
- 150000001340 alkali metals Chemical class 0.000 abstract 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 abstract 2
- 206010027452 Metastases to bone Diseases 0.000 abstract 1
- 208000025609 Urogenital disease Diseases 0.000 abstract 1
- 239000002671 adjuvant Substances 0.000 abstract 1
- 230000037396 body weight Effects 0.000 abstract 1
- 239000002775 capsule Substances 0.000 abstract 1
- 239000003085 diluting agent Substances 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- HEQWEGCSZXMIJQ-UHFFFAOYSA-M potassium;oxoarsinite Chemical compound [K+].[O-][As]=O HEQWEGCSZXMIJQ-UHFFFAOYSA-M 0.000 abstract 1
- 239000000843 powder Substances 0.000 abstract 1
- PTLRDCMBXHILCL-UHFFFAOYSA-M sodium arsenite Chemical compound [Na+].[O-][As]=O PTLRDCMBXHILCL-UHFFFAOYSA-M 0.000 abstract 1
- 239000003826 tablet Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/36—Arsenic; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Otolaryngology (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
- Production Of Liquid Hydrocarbon Mixture For Refining Petroleum (AREA)
- Luminescent Compositions (AREA)
Abstract
Composiciones farmacéuticas y métodos para el tratamiento de enfermedades urogenitales y metástasis osea en un humano, dicha composicion farmacéutica contiene una cantidad efectiva de sal de metal alcalino o alcalino térreo de ácido arsenioso y/o un adyuvante farmacéuticamente aceptable. De acuerdo con la presente, la sal de metal alcalino de ácido arsenioso es meta-arsenito de sodio (AsSO2Na) o meta-arsenito de potasio (AsO2K). La cantidad efectiva de sal de metal alcalino o alcalino térreo de ácido arsenioso es 0,0001-1500 mg/kg, preferentemente 1-1100 mg/kg, más preferentemente 1-150 mg/kg, y aun más preferentemente 50-100 mg/kg de peso corporal/día. La forma de administracion de las composiciones farmacéuticas de la presente es preferentemente oral, tales como una tableta, cápsula, polvo y/o solucion con un portador, diluyente o excipiente farmacéuticamente aceptable.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05076071A EP1721615A1 (en) | 2005-05-09 | 2005-05-09 | Pharmaceutical compositions comprising sodium or potassium arsenite for the treatment of urogenital cancer and its metastasis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR054448A1 true AR054448A1 (es) | 2007-06-27 |
Family
ID=35197739
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP060101851A AR054448A1 (es) | 2005-05-09 | 2006-05-09 | Composiciones farmaceuticas que comprenden acido arsenioso, su sal de sodio y sus derivados destinada al tratamiento de cancer urogenital y de su metastasis |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US20090011047A1 (es) |
| EP (5) | EP1721615A1 (es) |
| JP (1) | JP5026408B2 (es) |
| KR (3) | KR20160035101A (es) |
| CN (2) | CN101277707A (es) |
| AR (1) | AR054448A1 (es) |
| AU (1) | AU2006244767B2 (es) |
| BR (1) | BRPI0608716A2 (es) |
| CA (3) | CA2840609C (es) |
| CY (2) | CY1113475T1 (es) |
| DK (2) | DK3067068T3 (es) |
| ES (2) | ES2394264T3 (es) |
| HU (1) | HUE046029T2 (es) |
| IL (3) | IL187220A (es) |
| LT (1) | LT3067068T (es) |
| PL (2) | PL3067068T3 (es) |
| PT (1) | PT1885380E (es) |
| RU (1) | RU2401662C2 (es) |
| SG (5) | SG177983A1 (es) |
| SI (2) | SI1885380T1 (es) |
| TW (5) | TW201615200A (es) |
| WO (1) | WO2006121280A1 (es) |
| ZA (1) | ZA200710559B (es) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1721615A1 (en) | 2005-05-09 | 2006-11-15 | Komipharm International Co., Ltd. | Pharmaceutical compositions comprising sodium or potassium arsenite for the treatment of urogenital cancer and its metastasis |
| US8945505B2 (en) * | 2007-02-02 | 2015-02-03 | Panaphix, Inc. | Use of arsenic compounds for treatment of pain and inflammation |
| US20090246291A1 (en) * | 2008-03-27 | 2009-10-01 | Angelika Burger | Method and compositions for treatment of cancer |
| US20120045520A1 (en) * | 2008-08-21 | 2012-02-23 | Sang Bong Lee | Pharmaceutical composition comprising arsenite for the treatment of malignancy |
| CN107412771A (zh) * | 2009-09-10 | 2017-12-01 | 柯密纳克斯公司 | 靶向癌症干细胞的耐药性癌症疗法 |
| BR112012008310A2 (pt) * | 2009-09-18 | 2017-06-06 | Kominox Inc | métodos para tratamento de tumores cerebrais |
| WO2011086137A1 (en) * | 2010-01-13 | 2011-07-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Promyelocytic leukemia protein as a redox sensor |
| BR112013017499A2 (pt) * | 2011-01-11 | 2016-09-27 | Univ Basel | combinação de sirosingopina e inibidores mitocondriais para o tratamento de câncer e imunossupressão |
| US20120251628A1 (en) * | 2011-03-30 | 2012-10-04 | Young Joo Min | Compositions and methods for treatment of cancer |
| KR101309844B1 (ko) * | 2013-03-15 | 2013-09-23 | 박상채 | 항암 활성 증진용 한약재 및 이의 제조방법 |
| RU2618405C1 (ru) * | 2015-12-31 | 2017-05-03 | Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации | Способ определения продолжительности адъювантной химиотерапии при местно-распространенном колоректальном раке с метастазами в регионарные лимфоузлы после радикальных оперативных вмешательств |
| US10806768B2 (en) * | 2016-05-26 | 2020-10-20 | Stephen N. Pitcher | Composition for promoting metallothionein production |
| TWI808060B (zh) | 2016-12-01 | 2023-07-11 | 澳大利亞商益友製藥私人有限公司 | 砷組成物 |
| CA3091678A1 (en) | 2018-02-26 | 2019-08-29 | R.P. Scherer Technologies, Llc | Pharmaceutical dosage form for an emulsion of simethicone and loperamide |
| AU2019239671B2 (en) * | 2018-03-22 | 2025-02-27 | Komipharm International Australia Pty Ltd | Pharmaceutical composition comprising meta arsenite and method of manufacture |
| WO2019234112A1 (en) * | 2018-06-05 | 2019-12-12 | Katholieke Universiteit Leuven | Combination treatment of arsenic oxide and antiandrogens |
| CN115243692A (zh) * | 2020-02-16 | 2022-10-25 | 科微范国际澳大利亚私人有限公司 | 使用偏亚砷酸盐的治疗方法 |
| KR20220020635A (ko) * | 2020-08-12 | 2022-02-21 | 이상봉 | 탈모방지 또는 발모촉진용 외용제 조성물 |
| KR20220020633A (ko) * | 2020-08-12 | 2022-02-21 | 이상봉 | 탈모방지 또는 발모촉진용 주사제 조성물 |
| KR20220020637A (ko) * | 2020-08-12 | 2022-02-21 | 이상봉 | 항암화학요법이나 방사선요법으로 인한 암 환자의 탈모증을 포함한 탈모증 환자에 대하여 탈모를 방지하고 발모를 촉진하는 메타아르세나이트의 염을 함유하는 경구 투여용 약학적 조성물 |
| CN112336746A (zh) * | 2020-10-23 | 2021-02-09 | 内蒙古科技大学包头医学院 | 一种膀胱癌灌注化疗药物及其应用 |
| CN116549741B (zh) * | 2022-01-29 | 2025-04-11 | 中国科学院上海硅酸盐研究所 | 一种具有抑癌抗菌作用的表面改性镍钛合金材料及其制备方法和应用 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4166452A (en) | 1976-05-03 | 1979-09-04 | Generales Constantine D J Jr | Apparatus for testing human responses to stimuli |
| US4256108A (en) | 1977-04-07 | 1981-03-17 | Alza Corporation | Microporous-semipermeable laminated osmotic system |
| FR2431686A1 (fr) | 1978-07-20 | 1980-02-15 | Nestle Sa Soc Ass Tech Prod | Mecanisme de dosage et d'equilibrage et machine de remplissage comprenant un tel mecanisme |
| US4265874A (en) | 1980-04-25 | 1981-05-05 | Alza Corporation | Method of delivering drug with aid of effervescent activity generated in environment of use |
| KR930001917A (ko) * | 1991-07-26 | 1993-02-22 | 김두석 | 악성 종양 치료제의 제조방법 |
| RU2035181C1 (ru) * | 1994-02-18 | 1995-05-20 | Тамара Васильевна Воробьева | Средство для лечения лейкозов и способ лечения лейкозов |
| WO1995022336A1 (en) | 1994-02-18 | 1995-08-24 | Tamara Vasilievna Vorobieva | Agent having an immunomodulating effect and reducing disturbed functioning of the tissue cell propagation regulating system |
| ES2358624T3 (es) * | 1997-10-15 | 2011-05-12 | Polarx Biopharmaceuticals, Inc. | Composiciones y métodos para el tratamiento de enfermedades neoplásicas primarias y metastásicas usando compuestos de arsénico. |
| EP2255800B1 (en) | 1997-11-10 | 2012-10-17 | Memorial Sloan Kettering Cancer Center | Arsenic trioxide for use in the treatment of leukaemia |
| CN1233476A (zh) * | 1998-04-24 | 1999-11-03 | 陆道培 | 治疗急性白血病的药物及其制备方法 |
| KR20020083678A (ko) * | 2001-04-28 | 2002-11-04 | 주식회사 한국미생물연구소 | 아르세닉산나트륨 염, 소디움 메타아르세나이트 또는 이의혼합물을 함유한 항암제 조성물 |
| TW200408407A (en) | 2001-11-30 | 2004-06-01 | Dana Farber Cancer Inst Inc | Methods and compositions for modulating the immune system and uses thereof |
| EP2042182B1 (en) * | 2002-04-10 | 2013-05-22 | Komipharm International Co., Ltd. | Pharmaceutical composition comprising arsenite for the treatment of malignancy |
| KR100632250B1 (ko) * | 2004-02-16 | 2006-10-11 | 정태호 | 비소 화합물을 유효성분으로 하는 항암제 |
| US20060104292A1 (en) | 2004-11-15 | 2006-05-18 | Gupta Vivek G | System and methods for supporting multiple communications interfaces with single client interface |
| EP1721615A1 (en) | 2005-05-09 | 2006-11-15 | Komipharm International Co., Ltd. | Pharmaceutical compositions comprising sodium or potassium arsenite for the treatment of urogenital cancer and its metastasis |
| US8945505B2 (en) | 2007-02-02 | 2015-02-03 | Panaphix, Inc. | Use of arsenic compounds for treatment of pain and inflammation |
| US20090246291A1 (en) | 2008-03-27 | 2009-10-01 | Angelika Burger | Method and compositions for treatment of cancer |
| CN107412771A (zh) | 2009-09-10 | 2017-12-01 | 柯密纳克斯公司 | 靶向癌症干细胞的耐药性癌症疗法 |
-
2005
- 2005-05-09 EP EP05076071A patent/EP1721615A1/en not_active Withdrawn
-
2006
- 2006-05-09 DK DK16162414T patent/DK3067068T3/da active
- 2006-05-09 US US11/631,962 patent/US20090011047A1/en not_active Abandoned
- 2006-05-09 SG SG2012003091A patent/SG177983A1/en unknown
- 2006-05-09 EP EP16162414.3A patent/EP3067068B1/en active Active
- 2006-05-09 KR KR1020167007395A patent/KR20160035101A/ko not_active Ceased
- 2006-05-09 BR BRPI0608716-7A patent/BRPI0608716A2/pt not_active Application Discontinuation
- 2006-05-09 KR KR1020157017831A patent/KR20150085122A/ko not_active Ceased
- 2006-05-09 SI SI200631444T patent/SI1885380T1/sl unknown
- 2006-05-09 PT PT06732912T patent/PT1885380E/pt unknown
- 2006-05-09 LT LT16162414T patent/LT3067068T/lt unknown
- 2006-05-09 TW TW105102103A patent/TW201615200A/zh unknown
- 2006-05-09 AU AU2006244767A patent/AU2006244767B2/en not_active Ceased
- 2006-05-09 TW TW101132058A patent/TWI539957B/zh active
- 2006-05-09 ES ES06732912T patent/ES2394264T3/es active Active
- 2006-05-09 JP JP2008511051A patent/JP5026408B2/ja active Active
- 2006-05-09 WO PCT/KR2006/001731 patent/WO2006121280A1/en not_active Ceased
- 2006-05-09 TW TW104124162A patent/TWI574692B/zh not_active IP Right Cessation
- 2006-05-09 SI SI200632358T patent/SI3067068T1/sl unknown
- 2006-05-09 SG SG10202100785PA patent/SG10202100785PA/en unknown
- 2006-05-09 EP EP11165670.8A patent/EP2361628A1/en not_active Ceased
- 2006-05-09 CN CNA2006800250320A patent/CN101277707A/zh active Pending
- 2006-05-09 AR ARP060101851A patent/AR054448A1/es unknown
- 2006-05-09 CA CA2840609A patent/CA2840609C/en active Active
- 2006-05-09 KR KR1020077028751A patent/KR101413731B1/ko active Active
- 2006-05-09 EP EP06732912A patent/EP1885380B1/en active Active
- 2006-05-09 DK DK06732912.8T patent/DK1885380T3/da active
- 2006-05-09 HU HUE16162414A patent/HUE046029T2/hu unknown
- 2006-05-09 CA CA2608035A patent/CA2608035C/en active Active
- 2006-05-09 SG SG10201405278SA patent/SG10201405278SA/en unknown
- 2006-05-09 RU RU2007145489/14A patent/RU2401662C2/ru active
- 2006-05-09 SG SG2011075330A patent/SG175633A1/en unknown
- 2006-05-09 TW TW095116432A patent/TWI386214B/zh not_active IP Right Cessation
- 2006-05-09 PL PL16162414T patent/PL3067068T3/pl unknown
- 2006-05-09 CA CA2926846A patent/CA2926846C/en active Active
- 2006-05-09 PL PL06732912T patent/PL1885380T3/pl unknown
- 2006-05-09 CN CN201510064962.8A patent/CN104758312A/zh active Pending
- 2006-05-09 SG SG10201602555WA patent/SG10201602555WA/en unknown
- 2006-05-09 ES ES16162414T patent/ES2754372T3/es active Active
- 2006-05-09 TW TW103132530A patent/TWI522105B/zh not_active IP Right Cessation
- 2006-05-09 EP EP14166070.4A patent/EP2762145A1/en not_active Ceased
-
2007
- 2007-11-07 IL IL187220A patent/IL187220A/en active IP Right Grant
- 2007-12-04 ZA ZA200710559A patent/ZA200710559B/xx unknown
-
2012
- 2012-10-10 CY CY20121100940T patent/CY1113475T1/el unknown
-
2013
- 2013-12-17 IL IL229975A patent/IL229975A/en active IP Right Grant
-
2016
- 2016-03-22 US US15/077,373 patent/US11464859B2/en active Active
- 2016-03-22 IL IL244728A patent/IL244728A0/en unknown
-
2019
- 2019-11-06 CY CY20191101162T patent/CY1122522T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR054448A1 (es) | Composiciones farmaceuticas que comprenden acido arsenioso, su sal de sodio y sus derivados destinada al tratamiento de cancer urogenital y de su metastasis | |
| ES2647216T3 (es) | Compuestos policíclicos de carbamoilpiridona y su uso farmacéutico | |
| EA200901277A1 (ru) | Фармацевтические составы, содержащие пропиленгликольгидрат дапаглифлозина | |
| ES2916604T1 (es) | Ensayos de detección de nrf2 y métodos y composiciones relacionados | |
| UA107112C2 (uk) | Активатори розчинної гуанілатциклази | |
| MXPA01006474A (es) | Derivados colquinol como agentes perjudiciales vasculares. | |
| IL314360A (en) | Method of synthesizing thyroid hormone analogs and polymorphs thereof | |
| MX346879B (es) | Formulaciones de ketorolaco listas para su uso. | |
| IL187183A0 (en) | Pharmaceutical formulation of apomorphine for buccal administration | |
| GEP20135734B (en) | Pharmaceutical composition containing salt of strontium, vitamin d and cyclodextrin | |
| SI1891038T1 (sl) | Substituirani n-arilpirolodini kot selektivni modulatorji androgenskega receptorja | |
| PL2018379T3 (pl) | Sole skopiny oraz ich zastosowanie w sposobach wytwarzania N-demetylo-tiotropium i bromku tiotropium | |
| JO3406B1 (ar) | عملية لتصنيع منتج صيدلاني يشتمل على حمض الستريك ،أكسيد ماغنسيوم، بيكربونات بوتاسيوم وبيكو كبريتات صوديوم، تركيبة صيدلانية تشتمل على حبيبات متحصل عليها بواسطة هذه العملية ومنتجات وسيطة منها | |
| NZ596047A (en) | Stabilized lipid formulation of apoptosis promoter | |
| UA102885C2 (ru) | Таблетка для орального введения, которая содержит тамсулозин и солифенацин | |
| IN2012DN02502A (es) | ||
| RU2013154355A (ru) | Способ лечения мезотелиомы ингибитором рi3к | |
| IN2015DN03921A (es) | ||
| AR095159A2 (es) | Una composición farmacéutica en forma de cápsula para administración oral | |
| PH12013500173A1 (en) | Oral controlled release pharmaceutical compositions of blonanserin | |
| MXPA05013607A (es) | Candidatos de farmaco farmaceuticos mejorados y metodos para preparar los mismos. | |
| SG158863A1 (en) | Intravenous formulations of pde-5 inhibitors | |
| RU2015111491A (ru) | Комбинация макроциклического ингибитора протеазы hcv, ненуклеозидного ингибитора hcv и ритонавира | |
| TW200517367A (en) | Improved pharmaceutical drug candidates and methods for preparation thereof | |
| GB2429916A (en) | Pharmaceutical composition containing a stable and clear solution of anti-inflammatory drug in soft gelatin capsule and process for producing the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |